Table 1.

Summary of results from non-randomised clinical trials

Study	Drug	Population	n	ORR	OS
CheckMate-00324	Nivolumab	NSCLC previously treated	129	17%	9.9 months
CheckMate-06325	Nivolumab	SCC previously Treated	117	14.5%	8.2 months
KeyNote-00126	Pembrolizumab	NSCLC 80% previously treated	495	19.4%	12 months
PCD4989 g27	Atezolizumab	NSCLC 89% previously treated	88	23%	16 months
Javelin28	Avelumab	NSCLC 99% previously treated	184	13.6%	8.4 months
Rizvi29	Durvalumab	NSCLC 88% previously treated	228	16%	8.9 months (PD-L1 −) NR (PD-L1 +)

NSCLC, non-small cell lung cancer; ORR, objective response rate; OS, overall survival; PD-L1, programmed death receptor ligand-1.